Background: Current management for chronic pancreatitis in cats is largely symptomatic. Anecdotal reports suggest that immunomodulatory treatment can be helpful in some cases, but limited data is available.
Objectives: Compare the effects of symptomatic treatments alone, an immunosuppressive dosage of prednisolone, or modified cyclosporine on serum feline pancreatic lipase immunoreactivity (fPLI) concentration and clinical activity index (CAI).
Animals: Forty-eight client-owned cats with a presumptive diagnosis of chronic pancreatitis were managed on an outpatient basis.
Methods: Three-week randomized open-label trial with a nonrandomized active control. Owners elected to join either the control or the treatment group; cats enrolled in the treatment group were randomized to receive either prednisolone or cyclosporine. Serum fPLI concentration and clinical signs were recorded at baseline and on Days 10 and 21.
Results: The average decrease in serum fPLI concentration was 13.0 μg/L (95% CI, -23.9 to -0.9 μg/L) larger for the cyclosporine group (n = 17) than for the control group (n = 16) and 27.6 μg/L (95% CI, -41.2 to -11.4 μg/L) larger than for the prednisolone group (n = 15). The average decrease in CAI was 1.9 points (95% CI, -2.7 to -1.2) larger for the prednisolone group than for the control group and 1.2 points (95% CI, -2.1 to -0.4) larger than for the cyclosporine group.
Conclusions: Over a 3-week treatment period, cats with presumed chronic pancreatitis that received cyclosporine had a larger decrease in serum fPLI concentration compared with cats that were treated with an immunosuppressive dosage of prednisolone or cats that received only symptomatic treatments. However, clinical improvement was more apparent with prednisolone, but not cyclosporine.
Keywords: CsA; Spec fPL; corticosteroid; feline; hyperlipasemia; pancreas; pancreatic lipase.
© 2025 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.